A Multicenter Phase I Study of TCD-717 Given by 4-Hour Intravenous Infusion in Patients With Advanced Solid Tumors.

Trial Profile

A Multicenter Phase I Study of TCD-717 Given by 4-Hour Intravenous Infusion in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2014

At a glance

  • Drugs TCD 717 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors TCD Pharma
  • Most Recent Events

    • 07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 31 May 2012 Planned number of patients changed from 30 to 28 as reported by ClinicalTrials.gov.
    • 16 Feb 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top